Welcome to LookChem.com Sign In|Join Free

CAS

  • or

54509-63-6

Post Buying Request

54509-63-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

54509-63-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 54509-63-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,5,0 and 9 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 54509-63:
(7*5)+(6*4)+(5*5)+(4*0)+(3*9)+(2*6)+(1*3)=126
126 % 10 = 6
So 54509-63-6 is a valid CAS Registry Number.

54509-63-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-bromo-1-butoxy-2-fluorobenzene

1.2 Other means of identification

Product number -
Other names Benzene,4-bromo-1-butoxy-2-fluoro

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:54509-63-6 SDS

54509-63-6Relevant articles and documents

LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE

-

Paragraph 0229; 0231, (2018/03/01)

Shown are a liquid crystal compound satisfying at least one of physical properties such as high stability to heat and light, a high clearing point (or high maximum temperature), low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and satisfactory compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition. A compound is represented by formula (1), a liquid crystal composition contains the compound, or the like.

LIQUID CRYSTALLINE COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT EACH COMPRISING SAME

-

Page/Page column 37-38, (2012/01/11)

The invention provides a liquid crystal compound having general physical properties necessary for a liquid crystal compound, that is to say, stability to heat, light or the like, a small viscosity, a suitable value of refractive index anisotropy, a suitable value of dielectric anisotropy, steep characteristics electro-optic characteristics, a wide temperature range of a nematic phase and an excellent compatibility with other liquid crystal compounds, and a liquid crystal compounds especially having a wide temperature range of a nematic phase. A compound represented by formula (1). For example, R1 and R2 are each independently alkyl having 1 to 9 carbons or alkenyl having 2 to 9 carbons, alkoxy having 1 to 8 carbons or alkenyloxy having 2 to 8 carbons; Q1 and Q4 are each independently fluorine or chlorine; Q2 and Q3 are each independently hydrogen, fluorine or chlorine, and one of Q2 and Q3 is hydrogen; Z is -CH2O or -COO-; and h is 1 or 2.

Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors

-

Page 127, (2010/02/10)

This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 54509-63-6